

What is the safety/efficacy of the Novavax COVID-19 vaccine?

<https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc458>

Document Type: Rapid Review
Review Code: EOC220302 RR
Question Submitted: March 1, 2022
Date Completed: March 10, 2022
Status: 3. Completed
Research Team: EOC

Key Findings:

Novavax was authorized for use in Canada February 16, 2022 and has also been authorized for use in 35 other countries as a 2-dose primary series given as an intramuscular injection, 21 days apart

Phase 3 trials of Novavax in US/Mexico and UK showed an overall vaccine effectiveness of 89.7-90.4% against all severity COVID infection and 100% against moderate/severe infection and death

In the US/Mexico, vaccine effectiveness against the dominant Alpha variant was found to be 92.6%, while in the UK, it's effectiveness dropped to 86.3%

The most frequently reported local and systemic adverse events in both trials were tenderness and pain at the injection site and headache, myalgia and fatigue, respectively. Adverse events were mild-to-moderate and transient in nature, and more frequently reported following the second dose

A Phase 2 trial assessing safety and efficacy of Novavax in South Africa in adults 18-64 years during Beta dominance found a vaccine efficacy of only 49.4%, however, in subgroup analysis of only HIV negative individuals, efficacy rose to 60.1% overall, and 51% against the Beta variant. (). While efficacy against disease severity was not measured, the majority of infections reported in both the vaccine and placebo group were mild to moderate

Category: Clinical Management
Infection Prevention and Control

Subject: Infection Prevention and Control
Immunity
Risk
Vaccines

Population: All

Clinical Setting: Community
Primary care
Public Health

Priority Level: Level 2 One week (7 days)

Cite As: Badea, A; Groot, G; Reeder, B; Miller, L. What is the safety/efficacy of the Novavax COVID-19 vaccine? 2022 Mar 10. Document no.: EOC220302 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2022. 7 p. (CEST rapid review report).

Related Documents:

Evidence Search Report: EOC220302 ESR


Table: EOC220302 RR Table

Documents



EOC220302 RR

 Read PDF

 Download PDF